
MetLife (MET) Stock Forecast & Price Target
MetLife (MET) Analyst Ratings
Bulls say
MetLife is well positioned to compound earnings because its largest businesses—Group Benefits and RIS—contribute about 52% of 2025 adjusted earnings and benefit from scale, market leadership, and operating leverage. The company also has attractive growth engines in Asia, Latin America, and MIM, with capital-light mix shift, strong ROE of 16% in 2025 and 17% in 1H26, and a target of 4-7% near-term top-line growth in Group Benefits supporting a higher-quality earnings profile. Management’s AI and reinsurance initiatives, including Chariot Re’s capital raises and MIM’s AUM rising from about $625B to ~$750B, add fee upside, while disciplined underwriting and a favorable interest-rate backdrop support durable free cash flow and further ROE expansion.
Bears say
MetLife is exposed to meaningful downside from lower long-term interest rates, credit spread widening, and market volatility, all of which can pressure spread income, investment results, and liability stability across its large insurance and retirement books. Its earnings mix is also vulnerable because about 52% of 2025 adjusted earnings comes from Group Benefits and RIS, while Asia, Latin America, EMEA, and investment management add geographic and market-linked risks that can be amplified by FX, regulation, and competition. Even though the stock screens inexpensive at about 9.6x 2026E P/E and 8.8x 2027E P/E, that valuation discount reflects real concerns around alternative asset returns, wage and employment softness, and the sustainability of favorable mortality trends.
This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.
MetLife (MET) Analyst Forecast & Price Prediction
Start investing in MetLife (MET)
Order type
Buy in
Order amount
Est. shares
0 shares